Point-of-Care Testing for Hepatitis B DNA Shows High Accuracy in Clinical Trial, Expanding Access to Diagnosis and Treatment
核心洞察
A clinical trial led by the Kirby Institute at UNSW Sydney (搜索) demonstrated that point-of-care testing for hepatitis B DNA (搜索) using fingerstick blood samples is as effective as traditional laboratory testing.
The fingerstick point-of-care test provides results within 60 minutes and can be performed by a broader range of healthcare workers in small health clinics.
This breakthrough could significantly expand access to hepatitis B (搜索) testing and treatment in resource-limited settings and remote areas where current testing access is poor.
A clinical trial led by the Kirby Institute at UNSW Sydney (搜索) has demonstrated that point-of-care testing for hepatitis B DNA (搜索) using fingerstick blood samples is as effective as traditional laboratory testing, potentially revolutionizing access to diagnosis and treatment in underserved communities worldwide. The results, published in the Journal of Clinical Microbiology, could address a critical barrier in global hepatitis B (搜索) elimination efforts.
Breakthrough in Diagnostic Accuracy
"The results of our trial found that the fingerstick point-of-care test is highly accurate, closely matching the accuracy of traditional tests," explains Professor Gail Matthews, who led the research at the Kirby Institute. "This is a very important finding because it has the potential to expand access to testing and treatment globally, and especially in resource limited settings or remote areas, where current testing access is poor."
The point-of-care technology represents a significant advancement over current testing methods. Unlike traditional hepatitis B DNA (搜索) testing, which requires collecting venous blood samples for processing in centralized laboratories, the new approach uses a fingerstick blood sample that can be performed by a broader range of healthcare workers in small health clinics, delivering results within 60 minutes.
Addressing Critical Treatment Gaps
Hepatitis B DNA (搜索) testing plays a crucial role in determining treatment eligibility and monitoring therapeutic response. "Not everyone who has hep B needs treatment," explains Associate Professor Behzad Hajarizadeh, first author on the paper. "People with higher levels of the virus are more likely to benefit from treatment, so DNA tests are required to determine the levels of virus in the system. DNA testing is also used once a patient starts treatment, to help understand if the treatment is working."
Current testing protocols create significant barriers to care. Patients often need to travel long distances to access testing facilities and then wait days or weeks for results. This delay, combined with multiple clinic visits, can hinder timely treatment initiation and ongoing care management.
Global Health Impact
The timing of this breakthrough is particularly significant given the scale of the global hepatitis B (搜索) challenge. According to the most recent World Health Organization figures from 2022, an estimated 254 million people worldwide live with chronic hepatitis B infection (搜索). However, only 14% have been diagnosed and just 8% are receiving treatment, representing a major gap in global health coverage.
Hepatitis B (搜索) is responsible for over 1 million deaths annually, causing liver inflammation that can progress to serious complications including cirrhosis (搜索), liver failure (搜索), and liver cancer (搜索). While the infection is preventable through vaccination and effective treatments exist for chronic cases, access remains severely limited in many regions.
Supporting WHO Elimination Goals
The research findings align with recent policy developments. Most recent WHO guidelines include a new recommendation supporting the use of hepatitis B (搜索) point-of-care DNA fingerstick tests globally. Currently, no country is on track to meet the WHO target of eliminating hepatitis B as a public health threat by 2030.
"Our research demonstrates that point-of-care testing for hepatitis B DNA (搜索) using finger stick blood is, indeed, highly accurate and effective," says Associate Professor Tanya Applegate from the Kirby Institute. "Given the technology is already in use for a range of other infectious diseases globally, our evidence paves the way for integrating infectious disease care significantly enhancing access to hepatitis B (搜索) testing, monitoring and treatment, no matter where someone lives."
Implications for Healthcare Delivery
The technology builds on successful point-of-care testing implementations for other infectious diseases, including hepatitis C. However, until this study, the efficacy of hepatitis B DNA (搜索) testing using fingerstick blood samples remained unknown.
"Access to testing is a major barrier to progress on hepatitis B (搜索) elimination," says Associate Professor Thomas Tu from Hepatitis B Voices (搜索). "We are hopeful that this research will support the roll-out of point-of-care testing for hepatitis B, enhancing access and ultimately, improving health and saving lives."
The breakthrough is particularly relevant for populations in low- and middle-income countries, where the majority of people with chronic hepatitis B (搜索) live, and where access to testing and treatment remains severely limited. Even in high-income countries like Australia, hepatitis B DNA (搜索) testing can be difficult to access for people living in remote areas.